Literature DB >> 20965298

The role of membrane fusion activity of a whole inactivated influenza virus vaccine in (re)activation of influenza-specific cytotoxic T lymphocytes.

Natalija Budimir1, Tjarko Meijerhof, Jan Wilschut, Anke Huckriede, Aalzen de Haan.   

Abstract

Induction of cytotoxic T lymphocyte (CTL) activity against conserved influenza antigens, e.g. nucleoprotein (NP) could be a step towards cross-protective influenza vaccine. The major challenge for non-replicating influenza vaccines aiming for activation of CTLs is targeting of antigen to the MHC class I processing and presentation pathway of professional antigen presenting cells, in particular dendritic cells (DCs). Intrinsic fusogenic properties of the vaccine particle itself can enable direct cytosolic delivery of the antigen by enhancing release of the antigen from the endosome to the cytosol. Alternatively, the vaccine particle would need to possess the capacity to activate DCs thereby triggering cell-intrinsic mechanisms of cross-presentation, processes that do not require fusion. Here, using fusion-active and fusion-inactive whole inactivated virus (WIV) as a vaccine model, we studied the relative contribution of these two pathways on priming and reactivation of influenza NP-specific CTLs in a murine model. We show that activation of bone marrow-derived DCs by WIV, as well as reactivation of NP-specific CTLs in vitro and in vivo were not affected by inactivation of membrane fusion of the WIV particles. However, in vivo priming of naive CTLs was optimal only upon vaccination with fusion-active WIV. Thus, DC-intrinsic mechanisms of cross-presentation are involved in the activation of CTLs upon vaccination with WIV. However, for optimal priming of naive CTLs these mechanisms should be complemented by delivery of antigen to the cytosol mediated by the membrane fusion capacity of the WIV particles.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20965298     DOI: 10.1016/j.vaccine.2010.10.007

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Tailored vaccines targeting the elderly using whole inactivated influenza vaccines bearing cytokine immunomodulators.

Authors:  Tila Khan; Connie L Heffron; Kevin P High; Paul C Roberts
Journal:  J Interferon Cytokine Res       Date:  2013-10-08       Impact factor: 2.607

2.  Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.

Authors:  Natalija Budimir; Anke Huckriede; Tjarko Meijerhof; Louis Boon; Emma Gostick; David A Price; Jan Wilschut; Aalzen de Haan
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

3.  Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice.

Authors:  Tobias Kamphuis; Tjarko Meijerhof; Toon Stegmann; Julia Lederhofer; Jan Wilschut; Aalzen de Haan
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

4.  Influenza T-cell epitope-loaded virosomes adjuvanted with CpG as a potential influenza vaccine.

Authors:  Peter C Soema; Sietske K Rosendahl Huber; Geert-Jan Willems; Wim Jiskoot; Gideon F A Kersten; Jean-Pierre Amorij
Journal:  Pharm Res       Date:  2014-10-25       Impact factor: 4.200

5.  Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production.

Authors:  José Herrera-Rodriguez; Aurora Signorazzi; Marijke Holtrop; Jacqueline de Vries-Idema; Anke Huckriede
Journal:  Vaccine       Date:  2019-02-11       Impact factor: 3.641

6.  Full inactivation of human influenza virus by high hydrostatic pressure preserves virus structure and membrane fusion while conferring protection to mice against infection.

Authors:  Carlos H Dumard; Shana P C Barroso; Guilherme A P de Oliveira; Carlos A M Carvalho; Andre M O Gomes; José Nelson S S Couceiro; Davis F Ferreira; Dirlei Nico; Andrea C Oliveira; Jerson L Silva; Patrícia S Santos
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

7.  Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration.

Authors:  Natalija Budimir; Aalzen de Haan; Tjarko Meijerhof; Emma Gostick; David A Price; Anke Huckriede; Jan Wilschut
Journal:  Influenza Other Respir Viruses       Date:  2013-09-16       Impact factor: 4.380

8.  Superior in vitro stimulation of human CD8+ T-cells by whole virus versus split virus influenza vaccines.

Authors:  Benedict R Halbroth; Alexander Heil; Eva Distler; Martin Dass; Eva M Wagner; Bodo Plachter; Hans Christian Probst; Dennis Strand; Udo F Hartwig; Anita Karner; Gerald Aichinger; Otfried Kistner; Katharina Landfester; Wolfgang Herr
Journal:  PLoS One       Date:  2014-07-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.